Brief: Urica Therapeutics Announces Topline Data From The Phase 1 Clinical Trial Evaluating Dotinurad
29/06/2023 14:32
June 29 (Reuters) - Fortress Biotech Inc FBIO.O :
* URICA THERAPEUTICS ANNOUNCES TOPLINE DATA FROM THE PHASE 1
CLINICAL TRIAL EVALUATING DOTINURAD IN HEALTHY VOLUNTEERS IN THE
UNITED STATES
* URICA THERAPEUTICS: DATA SHOW COMPARABLE PHARMACOKINETIC,
PHARMACODYNAMIC AND SAFETY PROFILE BETWEEN U.S. AND JAPANESE
HEALTHY SUBJECTS
* URICA THERAPEUTICS: INITIATING PHASE 1B DOTINURAD
CLINICAL
TRIAL IN GOUT PATIENTS IN U.S. AND EXPECT TO BEGIN PIVOTAL
CLINICAL TRIALS IN 2024
Source text for Eikon: ID:nGNX3zzT4w
Further company coverage: FBIO.O
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi